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Summary
Background Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, 
few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy 
outcomes associated with ART initiated before conception compared with that of ART started after conception.
Methods We did a systematic review of studies from low-income, middle-income, and high-income countries by 
searching the Cochrane Central Register of Controlled Trials, Embase, LILACS, MEDLINE, Toxline, Web of Knowledge, 
and WHO Global Index Medicus and trials in progress (International Clinical Trials Registry Platform) for randomised 
trials, quasi-randomised trials, and prospective cohort studies done between Jan 1, 1980, and June 1, 2016, in which 
timing of ART initiation in pregnant women living with HIV was reported. We used the risk ratio (RR) and 
corresponding 95% CIs as the primary measure to assess the association between the selected outcomes and ART 
initiation before conception versus after conception. We used a random-eﬀ ects model to pool risk ratios.
Findings We included 11 studies with 19 189 mother–infant pairs. Women who started ART before conception were 
signiﬁ cantly more likely to deliver preterm (pooled RR 1·20, 95% CI 1·01–1·44) or very preterm (1·53, 1·22–1·92), or 
to have low-birthweight infants (1·30, 1·04–1·62) than were those who began ART after conception. Few data exist for 
neonatal mortality. The risk of very low birthweight, small for gestational age, severe small for gestational age, 
stillbirth, and congenital anomalies did not diﬀ er signiﬁ cantly between women who were taking ART before 
conception and those who began ART after conception.
Interpretation The beneﬁ ts of ART for maternal health and prevention of perinatal transmission outweigh risks, but 
data for the extent and severity of these risks are scarce and of low quality. As use of ART before conception rapidly 
increases globally, monitoring for potential adverse pregnancy outcomes will be crucial.
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article, there should be no suggestion that WHO endorses any speciﬁ c organisation, products or services. The use of 
the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.
Introduction
In 2013, WHO recommended that all pregnant and 
breastfeeding women with HIV infection should initiate 
combination antiretroviral therapy (ART) irrespective of 
clinical or immune status, and that ART be continued 
at least for the duration of mother-to-child transmission 
risk, with the option of continuing lifelong ART—an 
approach adopted by many low-income countries as a 
result of its programmatic and clinical beneﬁ ts.1 After the 
results of the TEMPRANO2 and START3 trials showed 
that beginning ART at higher CD4 cell counts (>500 cells 
per μL) was associated with signiﬁ cant clinical beneﬁ ts, 
in 2015, WHO recommended immediate initiation of 
lifelong ART for all HIV-infected individuals, including 
pregnant women.4 Thus, an increasing proportion of 
HIV-infected women will become pregnant while 
receiving ART.
ART started before conception and continued 
throughout pregnancy is associated with extremely low 
rates of mother-to-child transmission of HIV. In a report5 
from the UK and Ireland on 5652 deliveries between 
2007 and 2011, only four (0·19%) of 2105 women on ART 
before conception transmitted HIV to their infant. In the 
French Perinatal Cohort,6 no cases of mother-to-child 
transmission were noted among 2651 women who 
started ART before conception and had achieved viral 
suppression at delivery.
Lifelong ART for all HIV-infected pregnant women 
will not only contribute substantially to the global 
elimination of new paediatric HIV infections and 
improve maternal health and survival, but will also lead 
to a rapid rise in fetal exposure to antiretrovirals as 
pregnant and breastfeeding women started on ART have 
subsequent pregnancies. Despite nearly two decades of 
ART use during pregnancy, evidence for safety is scarce 
and conﬂ icting.7 ART use during pregnancy has been 
associated with increased risk of adverse birth outcomes, 
such as preterm delivery and low birthweight, in reports 
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from both high-income and low-income countries.8–11 
Some data suggest that adverse pregnancy outcomes 
could be speciﬁ cally associated with use of protease 
inhibitors during pregnancy;12–15 other data, including 
the results of a large population-based study in Botswana9 
and a study in Tanzania,16 suggest that such outcomes 
might also be associated with nevirapine-based or 
efavirenz-based ART. We did a systematic review to 
summarise the data about safety of, and adverse 
pregnancy outcomes associated with, ART initiated 
before conception compared with those of ART started 
after conception to inform the upcoming WHO 2015 
consolidated ART guidelines. We did not address 
potential longer-term eﬀ ects of in-utero ART exposure in 
HIV-exposed but uninfected children.
Methods
Inclusion criteria
We speciﬁ ed in advance the study background, 
rationale, and methods and documented them in a 
protocol to be published at the international prospective 
register of systematic reviews (PROSPERO number 
CRD42015025189). To be eligible for inclusion in 
our review, studies had to contain information 
about pregnancy outcomes after exposure to ART. 
The selection criteria we used to identify potential 
studies were study design (randomised trials, quasi-
randomised trials, and prospective cohort studies), study 
population (pregnant women living with HIV and 
receiving ART), intervention (ART initiation before 
conception), comparator (ART initiation after conception 
[ﬁ rst initiated during pregnancy]), and outcomes 
(prematurity, deﬁ ned as livebirth at <37 weeks’ gestation; 
very preterm delivery, deﬁ ned as livebirth at <34 weeks’ 
gestation; low birthweight [<2500 g]; very low birthweight 
[<1500 g]; small for gestational age, deﬁ ned as birthweight 
<10th centile for gestational age; severe small for 
gestational age, deﬁ ned as birthweight <3rd centile for 
gestational age; stillbirth, deﬁ ned as infant born with no 
signs of life ≥28 weeks’ gestation; maternal mortality; 
 Research in context
Evidence before this study
We did a systematic literature review of the Cochrane Central 
Register of Controlled Trials, Embase, LILACS, MEDLINE, Toxline, 
Web of Knowledge, and WHO Global Index Medicus and trials in 
progress (International Clinical Trials Registry Platform) to 
identify studies published between Jan 1, 1980, and 
June 1, 2016, in which pregnancy outcomes in pregnant women 
with HIV initiating antiretroviral therapy (ART) before 
conception were compared with those in women beginning 
ART after conception. We found 11 studies including 
19 189 women with HIV, 10 232 of whom started ART before 
conception and 8957 of whom started ART after conception. 
ART use during pregnancy has been associated with increased 
risk of adverse birth outcomes, such as preterm delivery and low 
birthweight, when compared with use of less complex regimens 
such as zidovudine prophylaxis in some studies in both low-
income and high-income countries. The results of some studies 
have suggested that adverse pregnancy outcomes could be 
speciﬁ cally associated with protease inhibitor use during 
pregnancy, but data from large studies in Botswana and 
Tanzania suggest such outcomes could also be linked to 
nevirapine-based or efavirenz-based ART. Very few data are 
available to allow comparison of pregnancy outcomes in 
women initiating ART before conception with outcomes in 
those beginning ART after conception. Until 2013, in 
low-income settings, where the largest proportion of women 
living with HIV are, WHO guidelines recommended use of 
lifelong ART during pregnancy only for pregnant women with 
low CD4 cell counts or advanced disease. Thus, the number of 
women who conceived while taking ART was low. In 
high-income settings, ART was recommended for all pregnant 
women, but until 2015, many women with high CD4 cell counts 
(>500 cells per μL) stopped ART after delivery. In some studies, 
use of ART before conception was compared with use of any 
regimen during pregnancy, including zidovudine alone, 
whereas in other studies ART use before conception was 
combined with ﬁ rst trimester use, without accounting for 
timing of ﬁ rst trimester initiation.
Added value of this study
To our knowledge, ours is the ﬁ rst systematic review that has 
speciﬁ cally assessed adverse pregnancy outcome risks by 
timing of initiation of ART (ie, before conception vs after 
conception). Although, reassuringly, many adverse outcomes, 
such as stillbirth, small for gestational age, and congenital 
abnormalities did not seem to diﬀ er by timing of ART 
initiation, we found that preterm delivery and low birthweight 
were signiﬁ cantly more likely in women who began ART before 
conception than in those who began ART after conception. 
However, data are sparse and of low to very low quality, and 
correlation with infant mortality or morbidity was not shown.
Implications of all available evidence
Although the clear beneﬁ ts of ART for maternal health and 
prevention of perinatal transmission outweigh potential risks, 
data for the extent or severity of these risks remain few and of 
poor quality. We showed an increased risk of preterm delivery 
and low birthweight associated with pre-conception initiation 
of ART, but there are potential confounders, because ART was 
used before conception primarily by women with low CD4 cell 
counts who were felt to require treatment for their health. In 
view of new guidelines for immediate ART in all individuals 
with HIV, use of ART before conception can be expected to 
increase rapidly worldwide, and will be crucial to monitor for 
potential adverse pregnancy outcomes.
For the international 
prospective register of 
systematic reviews see 
http://www.crd.york.ac.uk/
PROSPERO 
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neonatal mortality; and congenital anomalies, as deﬁ ned 
by the authors of the studies).
Data sources and searches
We systematically searched the Cochrane Central 
Register of Controlled Trials, Embase, LILACS, 
MEDLINE, Toxline, Web of Knowledge, and WHO 
Global Index Medicus and trials in progress 
(International Clinical Trials Registry Platform) for work 
published in any language between Jan 1, 1980, and 
June 30, 2016. Our search strategy is provided in the 
appendix; we used it to search MEDLINE and Embase 
via OVID, and adapted it to the other search engines. We 
also reviewed conference abstracts identiﬁ ed by our 
Embase search and from the International AIDS 
Conference, the annual Conference on Retroviruses and 
Opportunistic Infections, and the Conference on HIV 
Pathogenesis, Treatment, and Prevention (IAS) to ﬁ nd 
more recent relevant studies (our search of conference 
abstracts was restricted to those published between 
Jan 1, 2013, and June 30, 2016).
Additionally, hand searches of bibliographies of 
published systematic reviews and health technology 
assessments were done. We also manually searched 
ClinicalTrials.gov and the metaRegister of Controlled 
Trials to identify randomised controlled trials that had 
not yet been published but were potentially eligible 
for inclusion.
Study selection and data extraction
Two investigators (OAU and JBN), working independently, 
scanned all abstracts and proceedings identiﬁ ed in the 
search of published work and reviewed full-text versions 
of potentially relevant abstracts and proceedings. The 
same investigators then independently extracted data for 
study characteristics, interventions, patient characteristics 
at baseline, and outcomes (unadjusted and adjusted 
associations) for the study populations of interest for the 
ﬁ nal list of selected eligible studies. Any discrepancies 
between investigators were resolved through discussion 
until consensus was reached. We assessed the quality of 
evidence for the primary outcomes with the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) approach.17 For studies in which 
adjusted outcomes were not reported, we did not contact 
the authors for missing data, because doing so is usually 
time-intensive and the additional data requested are 
rarely acquired in our experience.
Statistical analysis
We used the risk ratio (RR) and corresponding 95% CIs as 
the primary measure to assess the association between the 
selected outcomes and ART initiation before conception 
versus after conception. We used a random-eﬀ ects model 
to combine data. The presence of statistical heterogeneity 
in the meta-analyses was assessed by reviewing the forest 
plot and applying a χ² test for heterogeneity with a 
threshold p value of 0·10 to determine signiﬁ cance. We 
used the I² value to quantify inconsistency across studies.18 
For preterm delivery, we used funnels plots and Egger 
tests19 to assess potential publication bias. Additionally, we 
did subgroup and meta-regression analyses to assess the 
inﬂ uence of study location (low-income and middle-
income economies vs high-income economies), calendar 
eﬀ ect (publication year), and small-study bias (sample 
size) on the pooled eﬀ ect estimates. We deﬁ ned 
signiﬁ cance at the α level of 0·05 for pooled adverse event 
estimates. This review was reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement.20
Role of the funding source
Staﬀ  (FR, SE, and MCD) of the study funder contributed 
to protocol development, data interpretation, and writing 
of the Article. All authors had full access to all the data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Our search of published work yielded 5309 citations after 
duplicates were removed (ﬁ gure 1). After review of the title 
and abstract, 187 full-text articles were selected for reading, 
and 11 studies met inclusion criteria (ﬁ gure 1).9,10,16,21–28 The 
studies included participants recruited during the period 
1986–2012 (table 1). Three were done in the UK,10,23,26 two in 
Botswana,9,28 and one each in Brazil,24 France,27 South 
Africa,25 and Tanzania;16 the remaining two studies21,22 
included participants from the European Collaborative 
Study (ECS). The median number of HIV-infected 
pregnant women included in each study was 443 (range 
159–8678; table 1).
Figure 1: Summary of evidence search and selection
6200 records identiﬁed through databases 
 searching
319 additional records identiﬁed through 
 other sources
5309 records after duplicates removed
5309 records screened
5122 records excluded
187 full-text articles assessed for eligibility
11 studies included in quantitative 
 synthesis (meta-analysis)
176 full-text articles excluded
For the metaRegister of 
Controlled Trials see www.isrctn.
com/page/mrct
See Online for appendix
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Prematurity was reported in ten studies.9,10,16,21,23–28 ART 
initiation before conception was associated with 
signiﬁ cantly higher risk of prematurity than ART 
initiation after conception (pooled RR 1·20, 95% CI 
1·01–1·44; ﬁ gure 2). Between-study heterogeneity was 
signiﬁ cant (I²=77%, 95% CI 57·3–87·4; p=0·0001), 
suggesting that about three-quarters of the variability in 
the measures of the association is due to heterogeneity 
between studies rather than chance (ﬁ gure 2). Subgroup 
analysis showed that the magnitude of the association 
was higher and signiﬁ cant in studies done in low-
income and middle-income countries (pooled RR 1·41, 
95% CI 1·22–1·63) than in those done in high-income 
countries, where the association was not signiﬁ cant 
(0·89, 0·54–1·47; ﬁ gure 2). However, these between-
group diﬀ erences were not signiﬁ cant (p=0·0857).
Our funnel plot seems symmetric, suggesting no 
evidence of publication bias (p=0·480 for Egger’s 
regression asymmetry test; ﬁ gure 3). Meta-regression 
analysis showed that publication year (ratio of RR 1·01, 
95% CI 0·93–1·10; p=0·736) and sample size (1·04, 
0·91–1·18; 0·558) were not signiﬁ cantly associated with 
the pooled risk ratio of the association.
Very preterm delivery was reported as an outcome in 
two studies.16,27 Initiation of ART before conception was 
associated with signiﬁ cantly higher risk of very preterm 
delivery than was ART initiation after conception (pooled 
RR 1·53, 95%CI 1·22–1·92, I²=23%; ﬁ gure 4). The same 
two studies included low birthweight as an outcome.16,27 
Pregnant women with HIV who started taking ART 
before conception were 30% more likely to have given 
birth to infants of low birthweight than were those who 
initiated ART after conception (pooled RR 1·30, 95% CI 
1·04–1·62; ﬁ gure 4).
The frequency of very low birthweight, which was an 
outcome in one study,16 did not diﬀ er signiﬁ cantly 
between women who initiated ART before conception 
and those who began ART after conception (pooled 
RR 0·18, 95% CI 0·02–1·51; ﬁ gure 4). Small for 
gestational age was an outcome in two studies,9,16 and 
severe small for gestational age was an outcome in one.16 
The overall risk of small for gestational age (1·13, 95% CI 
0·94–1·35) and severe small for gestational age (1·09, 
0·82–1·45) did not diﬀ er signiﬁ cantly between women 
who began ART before conception and those who did so 
after conception (ﬁ gure 4). Two studies reported 
stillbirth9,27 as an outcome: the risk of stillbirth in women 
who initiated ART before conception was not signiﬁ cantly 
diﬀ erent from that in women who began ART after 
conception (1·30, 0·99–1·69, I²=0%; ﬁ gure 4). Congenital 
anomalies was an outcome in one study.22 The overall risk 
of congenital anomalies did not diﬀ er signiﬁ cantly 
between women who initiated ART before conception 
and those who began ART after conception (1·24, 
0·61–2·49; ﬁ gure 4). 14 (1·8%) of 789 pregnant women 
with HIV who initiated ART before conception gave birth 
to infants with congenital anomalies, compared with 
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17 (1·4%) of 1184 women who initiated ART after 
conception (ﬁ gure 4).
None of the studies included maternal mortality as an 
outcome. Only one included neonatal mortality: Chen 
and colleagues9 reported that 2·3% of infants born to 
women with HIV died in the neonatal period. Neonatal 
mortality did not diﬀ er signiﬁ cantly between women 
who initiated ART before conception and those who 
started ART after conception (2·0% vs 2·3%; p=0·41). 
The median gestational age of infants who died was 
30 weeks (IQR 26–37); preterm infants had a 
signiﬁ cantly higher risk of neonatal death than did 
those born at term (7% vs 0·8%; p=0·0001). Similarly, 
infants who were small for gestational age had 
signiﬁ cantly higher risk of neonatal death than infants 
born at a birthweight expected for their gestational age 
(3·5% vs 1·5%, p=0·0001). Another risk factor for 
neonatal death in Chen and colleagues’ analysis9 was 
maternal hypertension (3·5% vs 1·5% for normotensive 
women; p=0·0002). Maternal CD4 T-cell count was not 
associated with risk of neonatal death (2·0% with CD4 
cell count <200 cells per μL vs 1·8% with >200 CD4 cells 
per μL; p=0·71).
On the basis of the GRADE approach, we judged the 
quality of the evidence to be low (for prematurity) to very 
low (for low birthweight, small for gestational age, 
stillbirth, and congenital abnormalities), reﬂ ecting that 
conﬁ dence in the estimates of eﬀ ect are uncertain and 
further research could change these estimates (table 2).
Discussion
In our systematic review and meta-analysis, preterm 
delivery, very preterm delivery, and low birthweight were 
signiﬁ cantly more common in pregnant women with 
HIV who initiated ART before conception than in women 
who ﬁ rst initiated ART after conception. On subgroup 
analysis, the magnitude of these associations was highest 
in studies done in low-income and middle-income 
countries (data not shown), where background rates of 
preterm delivery and low birthweight are higher than in 
high-income countries. Before the ART era, studies of the 
association between HIV infection and adverse pregnancy 
outcomes showed that HIV infection was signiﬁ cantly 
Figure 2: Forest plot of risk of preterm birth before 37 weeks (prematurity) in women with HIV who initiated ART before conception versus women who 
initiated ART after conception
Error bars are 95% CIs. Area of boxes represents the weight given to the study. The diamond represents the overall pooled eﬀ ect. The width of the line shows the 
95% CIs of the eﬀ ect estimate of individual studies. The width of the diamond shows the 95% CIs for the overall pooled eﬀ ect estimate. ART=antiretroviral therapy. 
Risk ratio
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Li et al (2016)16
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Thorne et al (2000)21
Random-eﬀects model
Heterogeneity: I2=77·7% (95% CI 46·3–90·7), p=0·0013
Random-eﬀects model
Heterogeneity: I2=76·8% (95% CI 57·3–87·4), p<0·0001
Test for overall eﬀect: p=0·0417
Test for subgroup diﬀerences: p=0·0857
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Figure 3: Contour-enhanced funnel plot of publication bias
p=0·48 for Egger’s regression asymmetry test.
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associated with adverse outcomes in low-income but not 
high-income countries.29
Although the results of some studies have suggested 
that increased risk of preterm delivery is conﬁ ned to 
protease-inhibitor-based ART,12–15 a range of regimens 
were used in the studies included in our review. For 
example, in Chen and colleagues’ study,9 which included 
3290 pregnant women with HIV receiving ART 
(2189 started before conception and 1101 started after 
conception), 2851 (87%) women were receiving nevirapine-
based ART and only 312 (9%) were receiving protease-
inhibitor-based ART (24 initiated before conception, 
278 initiated after conception). Similarly, in the study16 by 
Li and colleagues, 91% of women were receiving 
nevirapine-based ART, and 3% efavirenz-based ART.
Very few data were available for comparison of 
pregnancy outcomes between women initiating ART 
before conception and those beginning ART after 
conception. Until 2013, in low-income settings, where the 
largest proportion of women with HIV reside, WHO 
guidelines recommended use of ART during pregnancy 
only for pregnant women with low CD4 cell counts 
(<350 cells per μL) or advanced disease. Thus, the number 
of women who conceived while taking ART was low. In 
high-income settings, where ART was recommended for 
all pregnant women living with HIV, until 2015 many 
women with high CD4 cell counts (>500 cells per μL) 
stopped ART after delivery.
A potentially important source of bias is that women 
initiating ART before conception could have risk factors 
for adverse pregnancy outcomes not present in women 
ﬁ rst initiating ART after conception. For example, 
women initiating ART before conception might be older, 
more likely to be multigravidae, and more likely to have 
been initiated on ART because they were sick than 
women who start ART after conception, who might be 
more likely to be younger, healthier primigravidae who 
do not require ART for their own health. In Chen and 
Figure 4: Forest plot of risk of adverse outcomes in women with HIV who initiated ART before conception versus women who initiated ART after conception 
(and their oﬀ spring)
Error bars are 95% CIs. Area of boxes represents the weight given to the study. The diamond represents the overall pooled eﬀ ect. The width of the lines shows the 
95% CIs of the eﬀ ect estimate of individual studies. The width of the diamond shows the 95% CIs for the overall pooled eﬀ ect estimate. ART=antiretroviral therapy.
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Li et al (2016)16
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Heterogeneity not applicable for a single study
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Chen et al (2012)9
Mandelbrot et al (2015)27
Random-eﬀects model
Heterogeneity: I2=0%, p=0·7318
Congenital anomalies
Patel et al (2005)22
Random-eﬀects model
Heterogeneity not applicable for a single study
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colleagues’ Botswanan study,9 compared with those who 
initiated ART after conception, women on ART before 
conception were more likely to be older (32 years vs 
29 years, respectively), to be multigravidae (67% vs 47%), 
and to have a history of adverse pregnancy outcome (18% 
vs 13%). However, CD4 cell counts in the women starting 
ART before conception were higher than were those in 
women starting ART after conception (384 cells per μL vs 
225 cells per μL; proportion with <200 CD4 cells per μL 
2% vs 28%), and diﬀ erence between the two groups in 
other risk factors for adverse pregnancy outcomes (such 
as rates of syphilis or smoking) were not noted. 
Additionally, multivariate analyses that controlled for risk 
factors such as maternal age, parity, illicit drug use, and 
CD4 cell count were done in several of the larger 
studies,9,16,21,24 and associations were still signiﬁ cant. 
However, residual unmeasured confounding could still 
exist.
Another potential bias is that women who start ART 
very late in pregnancy (eg, after 36 weeks’ gestation) do 
not have the same opportunity for a preterm delivery as 
those starting earlier or before conception. However, in 
most studies, pre-conception and post-conception 
initiation of ART were compared without taking into 
account the gestational week that ART was begun, and 
median gestational age for those starting ART during 
pregnancy was not provided.
Strengths of our meta-analysis include the use of a 
predeﬁ ned protocol, a comprehensive search strategy, 
and involvement of two independent reviewers in all 
stages of the review process. To our knowledge, ours is 
the ﬁ rst systematic review in which measures of adverse 
pregnancy outcomes in women with HIV were pooled to 
address speciﬁ cally associations with initiation of ART 
before conception.
Our study also has some limitations. The review was 
limited by the scarcity of studies reporting most of the 
outcomes of interest. Although we examined for 
publication bias, we recognise that publication bias is 
always present when investigating routine outcomes from 
interventions widely provided in non-research settings. 
Also, all studies included were observational, which could 
lead to bias as a result of unmeasured confounding.
Several published studies did not diﬀ erentiate 
women initiating ART before conception from those 
initiating ART during the ﬁ rst trimester, and hence 
could not be included in our analysis. For example, a 
previous meta-analysis30 published in 2007 showed 
that ART use after conception did not increase pre-
term delivery overall, but initiation of combination 
ART before pregnancy or in the ﬁ rst trimester resulted 
in an increased risk of preterm delivery (odds ratio 1·71, 
95% CI 1·09–2·67) compared with initiation in 
the second or third trimester. The authors noted 
that increased surveillance is needed to quantify this 
risk accurately.
Additionally, in some studies, pre-conception initiation 
of ART was compared with initiation of various regimens 
during pregnancy, including zidovudine single-drug 
prophylaxis, and thus could not be included in our 
analysis. For example, in their large French study,11 
Sibiude and colleagues reported increased rates of 
preterm delivery in women who began ART before 
conception compared with women starting antiretroviral 
regimens during pregnancy. However, this study 
included use of zidovudine alone or dual antiretroviral 
Anticipated absolute eﬀ ects* Risk ratio 
(95% CI) 
Participants, n (studies) Quality of 
evidence 
(GRADE)
Risk with ART 
started after 
conception per 
1000 women
Risk with ART started 
before conception per 
1000 women (95% CI)
Prematurity (born alive before 37 weeks of 
pregnancy are completed)
170 203 (171–244) 1·20 (1·01–1·44) 17 216 (ten observational studies) Low†
Low birthweight (<2500 g) 188 244 (195–307) 1·30 (1·04–1·62) 1514 (two observational studies) Very low‡
Small for gestational age (birthweight less 
than the 10th centile for gestational age)
219 248 (206–296) 1·13 (0·94–1·35) 4152 (two observational studies) Very low‡
Stillbirth (born with no signs of life at or 
after 28 weeks’ gestation or miscarriage)
14 19 (14–24) 1·30 (0·99–1·69) 11 803 (two observational studies) Very low‡
Congenital anomalies 14 18 (9–36) 1·24 (0·61–2·49) 1973 (one observational study) Very low‡
According to the GRADE Working Group grades of evidence, evidence is of high quality when conﬁ dent that the true eﬀ ect lies close to that of the estimate of the eﬀ ect, of 
moderate quality when moderately conﬁ dent in the eﬀ ect estimate (the true eﬀ ect is likely to be close to the estimate of the eﬀ ect, but there is a possibility that it is 
substantially diﬀ erent), of low quality when conﬁ dence in the eﬀ ect estimate is limited (the true eﬀ ect could be substantially diﬀ erent from the estimate of the eﬀ ect), and of 
very low quality when there is very little conﬁ dence in the eﬀ ect estimate (the true eﬀ ect is likely to be substantially diﬀ erent from the estimate of eﬀ ect). GRADE=Grading of 
Recommendations Assessment, Development and Evaluation. *The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and 
the relative eﬀ ect of the intervention (and its 95% CI). †Inconsistency rated serious because heterogeneity in treatment eﬀ ect estimates was substantial (I²>50%). 
‡Inconsistency rated very serious because heterogeneity in treatment-eﬀ ect estimates was substantial (I²>75%); imprecision was rated serious because of the small number 
of studies (smaller than the optimal information size).
Table 2: GRADE summary of ﬁ nding, by outcome 
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prophylaxis.11 The Antiretroviral Pregnancy Registry 
compares use of diﬀ erent antiretroviral drugs in the ﬁ rst 
trimester with use in the second or third trimester, but 
does not provide data for pre-conception use or by type 
of regimen.31
Few investigators diﬀ erentiated between very preterm 
delivery (<34 weeks’ gestation) and preterm delivery 
(34–37 weeks’ gestation),16,27 or between very low 
birthweight (<1500 g) and low birthweight.16 Severe 
prematurity and low birthweight are associated with 
signiﬁ cantly more infant morbidity and mortality than 
are more moderate prematurity and birthweight. 
Additionally, reports of neonatal and infant mortality 
were lacking from all but one study. In Chen and 
colleagues’ report,9 ART initiation before conception was 
not associated with increased neonatal mortality 
compared with ART initiation after conception, despite 
being associated with higher risks of prematurity and low 
birthweight. Finally, spontaneous preterm delivery was 
not diﬀ erentiated from induced prematurity (induction of 
labour or caesarean section for complications) in any of 
the included studies.
The beneﬁ ts of ART for prevention of mother-to-child 
transmission of HIV and for maternal health clearly 
outweigh any risks identiﬁ ed so far, and there is no 
question that ART should be initiated in all pregnant 
women and continued thereafter. Nevertheless, further 
research is needed to deﬁ ne these risks better and to 
determine how to optimise ART to allow safe, healthy 
pregnancies for women with HIV and good health 
outcomes for both mother and child. With recom-
mendations for immediate initiation of ART after HIV 
diagnosis and 1·5 million pregnancies annually in 
women with HIV, fetal exposure to ART begun before 
conception will increase. Therefore, better monitoring of 
adverse pregnancy outcomes is essential to determine 
whether these outcomes are more common in people 
with HIV than in those without HIV. More research is 
needed to investigate causal mechanisms for adverse 
pregnancy outcomes with ART use to establish if 
modiﬁ able factors could be exploited to reduce or prevent 
such outcomes.32,33 Diﬀ erences in pregnancy outcomes 
between ART regimens need to be established, and a 
better understanding is needed of the ultimate eﬀ ect of 
such outcomes on maternal, neonatal, and infant 
morbidity and mortality.
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